NFKB1 and cancer: Conversely, caution may be required when considering using PIKfyve inhibitors in cancers driven by NF-κB signaling.93 Thus, these fundamental insights into DC regulation may inform optimal, “precision medicine” treatment strategies for further evaluation of PIKfyve inhibitors in specific cancers.